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Background We aimed to estimate the effect of anti-retroviral therapy (ART) on
incident tuberculosis (TB) in a cohort of HIV-infected children.
Methods We analysed data from ART-naı̈ve, TB disease-free children enrolled
between December 2004 and April 2008 into an HIV care program
in Kinshasa, Democratic Republic of Congo. To estimate the effect
of ART on TB incidence while accounting for time-dependent
confounders affected by exposure, a Cox proportional hazards
marginal structural model was used.
Results 364 children contributed 596.0 person-years of follow-up. At base-
line, the median age was 6.9 years; 163 (44.8%) were in HIV clinical
stage 3 or 4. During follow-up, 242 (66.5%) children initiated ART
and 81 (22.3%) developed TB. At TB diagnosis, 41 (50.6%) were
receiving ART. The TB incidence rate in those receiving ART was
10.2 per 100 person-years [95% confidence interval (CI) 7.4–13.9]
compared with 20.4 per 100 person-years (95% CI 14.6–27.8) in
those receiving only primary HIV care. TB incidence decreased with
time on ART, from 18.9 per 100 person-years in the first 6 months to
5.3 per 100 person-years after 12 months of ART. The model-
estimated TB hazard ratio for ART was 0.51 (95% CI 0.27–0.94).
Conclusions For HIV-infected children in TB-endemic areas, ART reduces the
hazard of developing TB by 50%.
Keywords HIV, tuberculosis, anti-retroviral therapy, children, marginal
structural model
Background
Extensive epidemiologic synergy exists between HIV
and tuberculosis (TB), particularly in sub-Saharan
Africa where up to 60% of individuals with TB are
HIV infected1 and TB is the most common cause of
morbidity and mortality among HIV-infected per-
sons.2 Since greater HIV-related immunodeficiency
increases TB susceptibility,3,4 immune reconstitution
following effective anti-retroviral therapy (ART)5
should decrease the incidence of TB. ART has been
observed to reduce TB incidence in HIV-infected
adults in settings including South Africa,6 the USA7
and Brazil.8
ART markedly improves clinical outcomes in chil-
dren in both resource-rich9 and resource-limited
settings.10 For HIV-infected children living in
resource-limited, TB-endemic communities, ART may
* Corresponding author. The University of North Carolina at
Chapel Hill, Department of Epidemiology, Chapel Hill, NC,
USA. E-mail: aedmonds@email.unc.edu
1 The University of North Carolina at Chapel Hill, Department
of Epidemiology, Chapel Hill, NC, USA.
2 The University of Kinshasa, School of Public Health,
Kinshasa, Democratic Republic of Congo.
3 The University of North Carolina at Chapel Hill, School of
Medicine, Chapel Hill, NC, USA.
Published by Oxford University Press on behalf of the International Epidemiological Association
 The Author 2009; all rights reserved. Advance Access publication 15 May 2009
International Journal of Epidemiology 2009;38:1612–1621
doi:10.1093/ije/dyp208
1612
have substantial and important effects on reducing TB
incidence and hence improving clinical outcomes.11–13
In this study, we report on an observational clinical
cohort of children participating in an HIV treatment
program in the Democratic Republic of Congo (DRC).
ART outcomes in a non-randomized setting are
likely to be biased by confounding by indication due
to baseline and time-dependent factors. Therefore, to
fulfill our primary aim of estimating the effect of ART
on incident TB, we relied on a Cox proportional
hazards marginal structural model (MSM).
Methods
Study design, population and measurements
This study was based at Kalembe Lembe Pediatric
Hospital in Kinshasa, DRC, where HIV-infected chil-
dren and first-line family members receive compre-
hensive HIV treatment and care, including ART if
indicated. Children with at least 1 week of follow-up
who were ART-naı̈ve, TB disease-free and <18 years of
age at HIV care initiation (between December 2004
and April 2008) were eligible for the study. HIV infec-
tion was verified by antibody testing. Children enrolled
at age <18 months with a presumptive diagnosis of
HIV were only included if the HIV diagnosis was
serologically confirmed at age 418 months.
At the initial HIV care visit, data were collected on
weight, age, history of previous TB treatment, World
Health Organization (WHO) HIV clinical stage and
CD4 cell count and percent. The decision to initiate
ART was made 1 week later (per protocol) based on
physician assessment and WHO14,15 and DRC16 anti-
retroviral guidelines. As clinically indicated, ART
could be initiated at any subsequent visit. The initial
prescribed regimen was stavudine (d4T), lamivudine
(3TC) and nevirapine (NVP), with zidovudine substi-
tuted for d4T in children weighing <15 kg. Patients
receiving ART were scheduled to visit monthly,
whereas patients not receiving ART were scheduled
to visit quarterly. Individuals needing acute medical
care also made unscheduled visits. Children did not
receive prophylaxis against TB. CD4 cell count and
percent were measured biannually at the DRC
National AIDS Reference Laboratory.
Physicans diagnosed TB based on symptoms, chest
X-ray (when available) and the Edwards scoring sys-
tem,17 a method in which points are assigned if clin-
ical symptoms, signs or history information suggestive
of childhood TB are present. In the absence of an
exact TB diagnosis date (n¼ 23), it was assumed
that TB was diagnosed on the 15th of the month
that TB treatment began. A lack of laboratory capacity
prevented routine HIV viral load and TB culture.
A four-level severity of immunodeficiency score
was calculated based on the 2006 WHO pediatric
anti-retroviral guidelines,15 using age and most
recent CD4 cell count. Level of undernutrition was
represented by the weight-for-age Z-score
(WAZ).18,19 WAZ was calculated using sex, weight
and age, and Centers for Disease Control and
Prevention growth chart standards.20
Parental informed consent for participation in the
HIV care program was obtained from all participants;
children 512 years of age also provided their assent.
The research was approved by the University of North
Carolina at Chapel Hill Institutional Review Board
and the Ethics Committee of the Kinshasa School of
Public Health.
Statistical analyses
Medians were compared by the Mann–Whitney test
and proportions were compared by the mean score or
chi-square test. We used an intention-to-treat
approach assuming that patients beginning ART
remained on therapy through to the end of follow-
up. Patients who initiated ART contributed person-
time to both the non-ART and ART groups; to the
non-ART group from enrollment until ART initiation,
and to the ART group from ART initiation until the
end of follow-up. Follow-up was defined as time from
HIV care enrollment to the first of TB diagnosis or one
of four censoring events: death, transfer of care, loss
to follow-up or the last clinic visit prior to analysis.
Children were classified as lost to follow-up if they
withdrew from the program or were not located by
three tracking attempts following a missed visit.
Unadjusted TB incidence rates and incidence rate
ratios were calculated under a Poisson distribution;
rates were expressed as number of events per 100
person-years.
We fit unadjusted pooled logistic models to estimate
crude hazard ratios (HRs) and 95% confidence inter-
vals (CIs) of the effect of time-dependent ART on
incident TB. We then performed multivariable analy-
ses by adding confounders measured at enrollment to
this model to estimate the effect adjusting for base-
line characteristics. Confounder selection was based
on a priori knowledge and a causal diagram. Effect
modification was assessed by comparing a main effects
model to models with interaction terms of ART and
other covariates via likelihood ratio testing (P < 0.10).
The effect of time-dependent ART on TB incidence
may be confounded by patient characteristics mea-
sured at enrollment (baseline), including history of
previous TB treatment, severity of immunodeficiency,
level of undernutrition, age and WHO HIV clinical
stage. Additionally, estimation of the effect of time-
dependent ART on incident TB must account for sev-
eral time-dependent confounders that are themselves
affected by prior ART. For example, severity of immu-
nodeficiency is an independent predictor of develop-
ing TB and initiating ART, and is itself influenced by
prior ART. In this study, we identified two such
covariates: severity of immunodeficiency based on
WHO pediatric guidelines, and level of undernutrition
based on WAZ. A directed acyclic graph depicts the
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causal effect of time-dependent ART on incident TB in
the presence of these two time-dependent factors that
are both confounders and intermediates (Figure 1).21
Standard epidemiological methods for effect estima-
tion are inadequate in the presence of time-dependent
confounders that are themselves affected by previ-
ous exposure.22 Therefore, we also fit Cox propor-
tional hazards MSMs to estimate the effect of
time-dependent ART on incident TB adjusting for
both baseline and time-dependent confounding.
After using each child’s covariate history to predict
subject and time-specific probabilities of treatment
and censoring via separate logistic regression
models, we constructed stabilized inverse-probability-
of-treatment-and-censoring (IPTC) weights. We then
estimated parameters of a Cox proportional hazards
MSM using an IPTC-weighted pooled logistic model.
Time was measured in person-days (a person-month
data structure gave identical results), and we carried
the last observation forward for missing covariate
data. The change in baseline hazard with time was
modeled with cubic splines (knots at the 5th,
27.5th, 50th, 72.5th and 95th percentiles of time),
and we relied on robust 95% CIs to account for
within-patient clustering.
Similar to other methodologies, our analyses assume
the absence of unmeasured confounders, absence of
unmeasured informative censoring, and no model
misspecification. All analyses were completed in SAS
(version 9.1.3; SAS Institute, Cary, NC, USA). Details
of fitting Cox proportional hazards MSMs, including
the SAS code, have been published.23
Results
The 364 HIV-infected children were a median of 6.9
years of age (interquartile range [IQR] 4.0–10.4) at
initiation of HIV care, and approximately one-half
were female (52.7%) (Table 1). The majority of chil-
dren were undernourished with a median WAZ of
2.4 (IQR 3.7 to 1.3), and 18.1% had previously
received TB treatment. Almost one-half (44.8%) of
patients had moderate to severe HIV disease progres-
sion with WHO HIV clinical stage 3 or 4, and 48.3%
were classified as having severe immunodeficiency
based on the WHO pediatric immunodeficiency scale.
ART was initiated by 242 children (66.5%), 189
(78.1%) of whom received d4T/3TC/NVP. During
follow-up, 24 children switched to a second-line or
alternative first-line regimen due to drug toxicity or
treatment failure. Age at entry to HIV care was com-
parable by ART use (P¼ 0.82); however, fewer
females than males initiated ART (P¼ 0.02).
Children who received ART, compared with those
who did not, started HIV care with more advanced
HIV disease as indicated by WHO HIV clinical stage,
CD4%, and level of immunodeficiency (all P < 0.01).
Additionally, prior TB treatment was more common
among children who received ART than those who
did not (21.9 and 10.7%, respectively; P < 0.01), as
was greater undernutrition (median WAZ 2.5 and
2.1, respectively; P¼ 0.05).
The majority of patients were followed until a first-
incident TB event (n¼ 81, 22.3%) or the end of study
follow-up (n¼ 244, 67.0%) (Figure 2). Twenty-three
(6.3%) children were lost to follow-up or transferred
their HIV care, with no difference as to whether the
patient started, or did not start, ART (8.2 vs 5.4%,
P¼ 0.30). Sixteen (4.4%) children died before an inci-
dent TB event or end of follow-up. Not accounting for
person-time under observation, the proportion of chil-
dren who died was smaller among those who
initiated ART than those who did not (3.3 vs 6.6%,
P¼ 0.15).
The 364 children contributed a total of 596.0 person-
years of follow-up, with a median follow-up duration
Figure 1 Directed acyclic graph representing the causal effect of time-dependent ART on incident TB, including
time-dependent measured confounders and unmeasured causal risk factors for incident TB. Numeric subscripts 0 and 1
denote the enrolment visit and subsequent visits, respectively
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of 23.2 months (IQR 7.5–30.3). Children who initiated
ART prior to an incident TB event or end of follow-up
were followed for a median of 26.1 months (IQR
11.1–34.9), with a median of 23.9 of those months
(IQR 8.6–28.7) occurring on ART since children
typically initiated ART shortly after starting
HIV care. Children who did not initiate ART were
followed for a shorter time, a median of 8.2 months
Table 1 Characteristics of 364 HIV-infected children initiating HIV care in Kinshasa, DRC, between December 2004 and
April 2008
Total (n¼ 364) ART (n¼ 242) No ART (n¼ 122) P-valuea
Baseline
Median age, years (IQR) 6.9 (4.0–10.4) 6.9 (4.0–10.5) 6.9 (4.3–9.9) 0.82
Age, years [n (%)]
<1 11 (3.0) 9 (3.7) 2 (1.6)
1–2 52 (14.3) 33 (13.6) 19 (15.6)
3–4 59 (16.2) 43 (17.8) 16 (13.1)
5þ 242 (66.5) 157 (64.9) 85 (69.7) 0.46
Female sex [n (%)] 192 (52.7) 117 (48.3) 75 (61.5) 0.02
HIV clinical stage (WHO) [n (%)]
1 68 (18.7) 32 (13.2) 36 (29.5)
2 133 (36.5) 74 (30.6) 59 (48.4)
3 147 (40.4) 123 (50.8) 24 (19.7)
4 16 (4.4) 13 (5.4) 3 (2.5) <0.01
Median CD4% (IQR) 16 (10–23) 13 (8–18) 23 (18–27) <0.01
Severity of immunodeficiencyb
(WHO) [n (%)]
Not significant 102 (28.7) 41 (17.2) 61 (52.1)
Mild 50 (14.0) 23 (9.6) 27 (23.1)
Advanced 32 (9.0) 21 (8.8) 11 (9.4)
Severe 172 (48.3) 154 (64.4) 18 (15.4) <0.01
History of TB treatment [n (%)] 66 (18.1) 53 (21.9) 13 (10.7) <0.01
Median WAZ (IQR) 2.4 (3.7 to 1.3) 2.5 (4.0 to 1.4) 2.1 (3.4 to 1.1) 0.05
Level of undernutrition [n (%)]
WAZ52 153 (42.0) 93 (38.4) 60 (49.2)
34WAZ <2 74 (20.3) 53 (21.9) 21 (17.2)
44WAZ <3 58 (15.9) 37 (15.3) 21 (17.2)
54WAZ <4 34 (9.3) 25 (10.3) 9 (7.4)
64WAZ <5 12 (3.3) 9 (3.7) 3 (2.5)
WAZ <6 33 (9.1) 25 (10.3) 8 (6.6) 0.06
Follow-up
Died [n (%)] 16 (4.4) 8 (3.3) 8 (6.6) 0.15
Follow-up loss or transfer [n (%)] 23 (6.3) 13 (5.4) 10 (8.2) 0.30
Total person-years accrued 596.0 469.4 126.6 N/A
ART person-years accrued 400.2 400.2 0.0 N/A
Median months follow-up (IQR) 23.2 (7.5–30.3) 26.1 (11.1–34.9) 8.2 (1.7–23.7) <0.01
Median months follow-up on ART (IQR) 8.5 (0.0–26.1) 23.9 (8.6–28.7) N/A N/A
Median number of program visits (IQR) 21 (9–36) 32 (15–39) 8 (4–17) <0.01
Developed incident TB [n (%)] 81 (22.3) 41 (16.9) 40 (32.8) <0.01
aP-values are for the comparison of children who received ART with children who did not receive ART.
bDoes not add to total due to missing data (percentages calculated from available data).
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(IQR 1.7–23.7) because they were more frequently lost
to follow-up or died, and were newer to the program
(ART is inevitably indicated as HIV progresses, so
children with longer follow-up were more likely to
initiate ART). While 469.4 person-years (78.8% of
total person-time) were contributed by children who
initiated ART, 400.2 person-years (67.1% of total
person-time) were accrued on ART. Overall, the
median number of visits was 21 (IQR 9–36).
According to protocol, children who received ART
were seen more often (median, 32 visits) than chil-
dren who did not receive ART (median, 8 visits).
Over one-half of children who initiated ART during
follow-up did so within 1 month of starting HIV care
(Table 2). While 64.4% of children who received ART
were severely immunodeficient at baseline, 76.5% of
these children were severely immunodeficient at time
of ART initiation. In a multivariable logistic regression
model adjusted for time since HIV care initiation,
advanced WHO HIV clinical stage at entry to HIV
care was strongly related to an increased probability
of receiving ART (Table 3). Time-updated severe
immunodeficiency was also strongly associated with
receiving ART. However, age, history of TB treatment
and level of undernutrition were not associated with
ART initiation.
Eighty-one (22.3%) children were diagnosed with
incident TB during follow-up. TB was diagnosed a
median of 6.2 months after HIV care initiation (IQR
1.6–11.6) at a median age of 7.7 years (Table 2).
Forty-five (55.6%) children had advanced or severe
immunodeficiency at time of TB diagnosis, and 41
(50.6%) were receiving ART.
Overall, the TB incidence rate was 13.6 per 100
person-years (95% CI 10.8–16.9), 10.2 per 100
person-years (95% CI 7.4–13.9) among children
receiving ART and 20.4 per 100 person-years
(95% CI 14.6–27.8) among children not receiving
ART. Therefore, the crude TB incidence rate ratio con-
trasting children receiving ART with those remaining
ART-naı̈ve was 0.50 (95% CI 0.32–0.80).
Among the 40 children who developed TB while
not receiving ART, the median time from enrollment
into HIV care to TB was 3.4 months (IQR 0.6–7.8).
Among the 41 children who developed TB while
receiving ART, the median time from enrollment to
TB was 7.5 months (IQR 3.6–14.1), and the median
time from ART initiation to TB was 6.5 months (IQR
1.9–13.9). Children appeared to be at greatest risk of
being diagnosed with TB shortly after starting
ART, with TB incidence rates dropping with longer
ART duration (Figure 3). Specifically, of the 41 TB
cases that developed among children receiving ART,
12 (29.3%) occurred during the first 3 months of
treatment, the period that ‘unmasking’ TB immune
reconstitution inflammatory syndrome (IRIS) is
believed to manifest most readily.24
In an unadjusted analysis, ART decreased the hazard
of being diagnosed with TB, with a HR of 0.64 (95%
CI 0.39–1.04). Adjusting for demographic and clinical
characteristics, including severity of immunodefi-
ciency and WHO HIV clinical stage at enrollment,
the HR was 0.54 (95% CI 0.29–0.99). Finally, based
on a Cox proportional hazards MSM that included all
potential confounders measured at enrollment and
time-dependent confounders, the HR was 0.51 (95%
CI 0.27–0.94) (Table 4). In addition to indicating
that ART lowered the risk of being diagnosed
with TB during follow-up, this model also suggested
that increased severity of WHO HIV clinical stage
and greater degree of undernutrition contributed to
a greater hazard of receiving a TB diagnosis. Age
and history of TB treatment were not associated
with TB.
Figure 2 Schematic overview of 364 HIV-infected children initiating HIV care in Kinshasa, DRC, between December 2004
and April 2008
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Discussion
This study is the first to estimate a causal effect of
ART on incident TB in HIV-infected children. A Cox
proportional hazards MSM, which controlled for time-
dependent covariates affected by prior ART, revealed
a strong protective effect of ART on incident TB
(HR 0.51, 95% CI 0.27–0.94). Our results were similar
to those from the only methodologically comparable
study, one of HIV-infected South African adults (HR
0.61, 95% CI 0.46–0.81).25 Whereas the small differ-
ence between the fully adjusted and unadjusted
results suggests minimal overall baseline and time-
dependent confounding in this clinical cohort, the
utilized analytic approach accounted for this potential
bias inherent to the observational, longitudinal
design.
The ART-related reduction in TB incidence that we
observed was similar to the 50–80% decrease seen in
previous studies of HIV-infected adults6–8 and chil-
dren,11,13 although studies using multivariable model-
ing did not appropriately account for time-dependent
confounding. Our unadjusted TB incidence rate ratio
for the effect of ART of 0.50 is close to the 0.58
observed among South African children.12
The substantial clinical benefits of ART on TB
outcomes are likely due to a combination of reduc-
tions in HIV RNA replication and quantitative
and functional immune reconstitution. Although the
full benefits of ART on cellular immunity are to date
poorly understood,26 partial restoration of specific
anti-mycobacterial immune responses in children
have been documented.27 The observed decrease in
TB incidence with increasing time on ART also
makes logical sense, as ART restores HIV-damaged
immunity over time.28 A study of South African
adults suggests lower TB incidence rates after the
first year of ART.29
While the inclusion of only children with known
HIV infection precluded the comparison of TB inci-
dence in children receiving ART with that in children
without HIV, it is notable that the TB incidence
observed among children receiving ART (10.2 per
100 person-years, or 10 200 per 100 000) exceeds
Table 2 Clinical and demographic characteristics at time of TB diagnosis and ART initiation of HIV-infected children
initiating HIV care in Kinshasa, DRC, between December 2004 and April 2008
At time of incident TB (n¼ 81) At time of ART initiation (n¼ 242)
Median months accrued (IQR) 6.2 (1.6–11.6) 1.1 (0.9–2.7)
Median ART months accrueda (IQR) 6.5 (1.9–13.9) N/A
Median age, years (IQR) 7.7 (5.4–10.8) 7.2 (4.1–11.0)
Age, years [n (%)]
<1 3 (3.7) 4 (1.7)
1–2 11 (13.6) 34 (14.0)
3–4 10 (12.3) 42 (17.4)
5þ 57 (70.4) 162 (66.9)
Median CD4%b (IQR) 18 (10–24) 12 (8–16)
Severity of immunodeficiencyb,c
(WHO) [n (%)]
Not significant 27 (33.3) 29 (12.2)
Mild 9 (11.1) 13 (5.5)
Advanced 9 (11.1) 14 (5.9)
Severe 36 (44.4) 182 (76.5)
Median WAZ (IQR) 2.6 (4.2 to 1.4) 2.4 (3.9 to 1.4)
Level of undernutrition [n (%)]
WAZ52 28 (34.6) 98 (40.5)
34WAZ <2 20 (24.7) 55 (22.7)
44WAZ <3 9 (11.1) 35 (14.5)
54WAZ <4 9 (11.1) 25 (10.3)
64WAZ <5 8 (9.9) 7 (2.9)
WAZ <6 7 (8.6) 22 (9.1)
aAmong the 41 children who developed TB while receiving ART.
bAs CD4 was not usually measured the same day as TB diagnosis or ART initiation, these values are representative of the most
recent data at time of TB diagnosis or ART initiation.
cDoes not add to total due to missing data (percentages calculated from available data).
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surveillance-based TB incidence estimates in sub-
Saharan African children.30,31 It has been shown
that the incidence of TB in individuals receiving
ART, despite restored CD4 levels, may still be appre-
ciably higher than the TB incidence in HIV-negative
individuals.6,26,27 This discrepancy may be due to
deficiencies of reconstituted immune systems, a
notion supported by the inability of ART to restore
TB-specific, interferon-g secreting CD4 cells.32 HIV-
infected children may thus benefit from additional
interventions including adjunctive treatments such
as isoniazid prophylaxis,33 although possible drug
interactions with d4T currently used in first-line regi-
mens in resource-limited settings would require care-
ful consideration.34
The majority of children received a generic,
fixed-dose combination ART (d4T/3TC/NVP), with
Table 3 Baseline and longitudinal clinical and demographic
patient characteristics associated with ART initiation among
HIV-infected children initiating HIV care in Kinshasa, DRC,
between December 2004 and April 2008a
Characteristic HRb 95% CI
Age at baseline (years)
<1 Ref.
1–2 0.98 0.42, 2.28
3–4 1.58 0.68, 3.67
5þ 1.51 0.69, 3.31
Severity of immunodeficiency at
baseline (WHO)
Not significant Ref.
Mild 1.16 0.58, 2.313
Advanced 2.35 1.03, 5.37




Mild 1.21 0.53, 2.75
Advanced 1.52 0.61, 3.80
Severe 7.53 3.92, 14.49
HIV clinical stage at baseline (WHO)
1 Ref.
2 1.09 0.68, 1.74
3 2.09 1.29, 3.37
4 2.56 1.18, 5.53
History of TB treatment 1.17 0.80, 1.70
Level of undernutrition at baseline
WAZ52 Ref.
34WAZ <2 1.37 0.82, 2.31
44WAZ <3 1.23 0.67, 2.28
54WAZ <4 1.62 0.77, 3.40
64WAZ <5 1.69 0.68, 4.25
WAZ <6 1.63 0.58, 4.57
Level of undernutritionc
WAZ52 Ref.
34WAZ <2 0.63 0.38, 1.05
44WAZ <3 0.60 0.32, 1.13
54WAZ <4 0.43 0.20, 0.90
64WAZ <5 0.39 0.14, 1.10
WAZ <6 0.39 0.14, 1.13
aAmong the 356 children with complete covariate data at
baseline.




Table 4 Estimates from Cox proportional hazards MSM to
assess the causal effect of ART on incident TB among HIV-
infected children initiating HIV care in Kinshasa, DRC,




















History of TB treatment 0.90 0.50–1.63
Level of undernutrition
WAZ52 Ref.
34WAZ <2 1.13 0.61–2.11
44WAZ <3 1.20 0.57–2.52
54WAZ <4 2.16 1.04–4.45
64WAZ <5 1.47 0.43–5.06
WAZ <6 2.97 1.40–6.31
aAmong the 356 children with complete covariate data at
baseline. Parameters were approximated by stabilized IPTC-
weighted pooled logistic regression. Model includes baseline
covariates in the table along with a time-dependent intercept.
Ref¼Reference.
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split-drug dosages adjusted for body weight. Single-
dose NVP is the most common anti-retroviral regimen
used for the prevention of mother-to-child transmis-
sion (PTMCT) in resource-limited settings and resis-
tance frequently develops and persists in infected
infants.35,36 While there were no data on whether
the children had previously received NVP or whether
they harboured HIV variants with NVP-associated
mutations, it is anticipated that these scenarios were
uncommon given the short history and limited cover-
age of PMTCT services in Kinshasa.37 Additionally,
since HIV RNA levels were unavailable, we were
unable to assess virological response to ART. It is pos-
sible that a stronger protective effect of ART on
incident TB would have been observed if we were
able to identify the children who achieved and sus-
tained virological suppression.
Increased TB incidence rates at more advanced
immunodeficiency have been observed in children
and adults,1,13,29,38 and our results suggest an associ-
ation between WHO HIV clinical stage and TB.
Furthermore, we observed a trend between greater
undernutrition and TB, also reported in a prior pedi-
atric study.13
Diagnosis of TB in children, generally difficult and
further complicated by HIV infection,39,40 was ham-
pered in this resource-limited setting by limited access
to diagnostics. While it is not anticipated that outcome
ascertainment differed by ART use, children receiving
ART were seen more frequently than children not
receiving ART. Fewer visits among ART-naı̈ve children
may have led not only to an underestimation of TB
incidence in this group, but also to an underestima-
tion of the effect of ART on incident TB. Additionally,
the estimate may have been biased if children were
more likely to be diagnosed with TB because of inten-
sified case finding following program entry.
Lastly, this study could not address what proportion
of the observed high incidence of TB soon after ART
initiation was due to partial immune reconstitution or
unmasking IRIS,41 phenomena that may have
impacted our estimate of the effect of ART on TB.
The proportion of children initiating ART who devel-
oped unmasking TB IRIS has been observed to be
relatively low (7.4% in South Africa and even lower
in Thailand).13,42
In conclusion, ART had a strong, protective effect on
incident TB in HIV-infected children in Kinshasa,
DRC, through 2 years of therapy. Longer term
follow-up of pediatric HIV-infected cohorts in
resource-limited, TB-endemic areas is needed in
order to assess whether this protective effect is sus-
tained throughout the course of treatment.
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KEY MESSAGES
 Estimation of the causal effect of anti-retroviral therapy (ART) on incident tuberculosis (TB) in an
observational study requires epidemiological methods that account for time-dependent confounders
affected by prior exposure.
 ART was strongly protective against incident TB in a cohort of HIV-infected children in Kinshasa,
Democratic Republic of Congo.
 The incidence rate of TB was observed to decrease with increasing time on ART.
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mortality. This is especially so in African settings,
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